Iran Pharm.D. End-of-Course Exam common mistakes
Iran Pharm.D. End-of-Course Exam · Understand the traps and how to avoid them.
When asked to select the most bioavailable oral formulation, the candidate compares only the stated aqueous solubility or the labeled dose and ignores the dissolution rate, particle size, and first-pass extraction of the options.
Candidates memorize the definition of bioavailability as 'fraction of dose reaching systemic circulation' but never practice ranking formulations on the actual rate-limiting steps, so they default to the most familiar or highest-dose product.
What to do instead
Before answering, write the three determinants (release from dosage form, absorption across the enterocyte, hepatic/intestinal first-pass) and score each option against them; remember that a salt form or micronized particle improves dissolution rate, not equilibrium solubility, and that a drug with high extraction ratio loses more to first pass regardless of dose.
In pharmacokinetic calculations the candidate plugs numbers into equations without checking unit consistency, mixing mg with µg or hours with minutes, and reports a clearance or half-life off by factors of 60 or 1000.
Exam items often supply values in mixed units (dose in mg, concentration in µg/mL, time in minutes) to test dimensional reasoning, and candidates under time pressure grab the first formula that looks relevant.
What to do instead
Adopt a fixed routine: convert every input to base units (mg, L, h) in a written line before substitution, carry units through the equation, and sanity-check the result against known ranges (e.g., creatinine clearance in mL/min, half-life in hours); if the answer's magnitude is implausible for the drug class, recheck units first.
The candidate identifies a drug's receptor or enzyme target but cannot predict the functional consequence, for example calling a beta-2 agonist a vasoconstrictor or an ACE inhibitor a bradykinin antagonist.
Pharmacology is studied as a list of drug–target pairs without rehearsing the downstream signaling, so the candidate recalls the label but not the physiology that links target to effect and adverse effect.
What to do instead
For every major drug class, write a three-line chain: receptor → second messenger/tissue response → clinical effect plus the predictable adverse effect (e.g., beta-2 agonism → Gs/adenylyl cyclase → bronchodilation and tremor/tachycardia). Practicing this chain converts memorized names into mechanism-based reasoning that generalizes to unfamiliar drugs.
When asked to choose therapy for a patient with a comorbidity, the candidate selects the guideline first-line drug for the primary disease and ignores the contraindication created by the comorbidity or interacting medication.
Guidelines are memorized as single-disease algorithms, and candidates answer the 'what treats disease X' question rather than the 'what treats X in this patient' question the vignette actually poses.
What to do instead
Read the vignette twice: first list the active problems and current medications, then for each candidate drug check the specific contraindication (e.g., NSAIDs in CKD or heart failure, metformin in eGFR below 30, beta-blockers in decompensated asthma). Eliminate options on the comorbidity before ranking efficacy.
The candidate calculates a pediatric or renal-adjusted dose but stops before verifying the maximum dose, the dosing interval, and the route, so the arithmetic is right but the regimen is unsafe or impractical.
Weight-based formulas (mg/kg) are drilled in isolation, and candidates treat the calculation as the endpoint rather than one step in regimen design.
What to do instead
Complete a four-step check every time: weight-based amount, cap against adult maximum, confirm interval matches the drug's half-life and indication, and confirm the route and formulation exist for that patient (e.g., a child who cannot swallow tablets). Show each step so partial credit is visible.
In structure–activity questions the candidate counts functional groups or matches the molecule to a familiar scaffold instead of locating the pharmacophore and the ionizable center at physiological pH.
Medicinal chemistry is revised by recognizing whole structures rather than by mapping which atoms make the required receptor contacts and which govern solubility and permeability.
What to do instead
Annotate each structure with pKa, the group ionized at pH 7.4, hydrogen-bond donors/acceptors, and the metabolically labile position; then answer whether the modification changes binding, solubility, or metabolic stability. Practice explaining why a bioisostere (e.g., replacing a carboxylic acid with a tetrazole) preserves activity while altering PK.
The candidate assumes a natural product is safe because it is 'herbal', overlooks standardized extract content and herb–drug interactions, and cannot name the marker compound used for quality control.
Pharmacognosy is often studied as botany and history, so candidates learn plant names and active classes but not the analytical and clinical consequences of variable extract composition.
What to do instead
For each major medicinal plant, memorize four items: the marker or active constituent, the pharmacological mechanism, the documented interaction or toxicity (e.g., St John's wort inducing CYP3A4, ginkgo increasing bleeding risk), and the pharmacopoeial identity test. Anchor the plant to a clinical scenario rather than to its taxonomy.
The candidate treats an analytical result as valid without questioning the method: comparing an HPLC assay to a spectrophotometric one, ignoring specificity, or accepting a result outside the validated linear range.
Quality-control questions are answered by recalling which technique is 'modern' rather than by evaluating fitness for purpose, and validation parameters are memorized as a list without operational meaning.
What to do instead
For any analytical scenario, state the analyte, matrix, and required sensitivity first, then check specificity, linearity range, LOD/LOQ, precision, and accuracy against that requirement. Remember that a UV method cannot distinguish a degradation product absorbing at the same wavelength, which is why chromatographic separation or a stability-indicating method is required.
In pathophysiology items the candidate names the disease and its classic symptom but cannot connect the disturbed physiology to the laboratory pattern or to the drug's target, so mixed acid–base or electrolyte questions are answered by pattern-matching the diagnosis.
Pathophysiology and clinical chemistry are revised separately from pharmacology, and candidates do not rehearse the causal chain from mechanism to lab value to therapeutic intervention.
What to do instead
Practice interpreting arterial blood gases and electrolytes stepwise (pH → primary disorder → compensation → anion gap) and then ask which transporter, enzyme, or hormone is deranged and which drug class corrects it. Writing the chain once per disorder (e.g., insulin deficiency → lipolysis → ketoacidosis → anion-gap metabolic acidosis) makes the lab and pharmacology questions converge.
The candidate answers pharmacy-practice and social/administrative items with general ethical sentiment instead of citing the specific legal classification, dispensing rule, or pharmacovigilance reporting obligation that the item tests.
These domains feel like common sense, so candidates skip the regulatory detail (controlled-drug schedules, prescription retention periods, ADR reporting timelines and who must report) and lose marks on precise, rule-based items.
What to do instead
Build a one-page regulatory reference sheet for the Iranian context: controlled-substance schedules and dispensing limits, prescription validity and retention, mandatory ADR reporting to the pharmacovigilance center, and Good Pharmacy Practice requirements. For each item, ask which specific rule is being tested and answer with the rule, not with a general principle.